ArticleFrontiers in veterinary science2025
On-site detection of MERS-CoV infections in a camel slaughterhouse in Kenya using a commercial rapid antigen test.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Middle East respiratory syndrome coronavirus (MERS-CoV) poses a significant public health risk, with dromedary camels being the primary reservoir hosts. Regular and systematic surveillance for MERS-CoV is limited by the lack of extensively validated, rapid, field-deployable diagnostic tools. Objective: We aimed to validate and implement a commercial MERS-CoV antigen test kit (Bionote, South Korea) for field surveillance of MERS-CoV in Kenya. Methods: We evaluated whether the Bionote MERS-CoV rapid antigen test can discriminate between two different MERS-CoV isolates representing clades A (EMC/2012) and C (Kenya/9954). We conducted an assay performance evaluation using 2,736 archived camel nasal swab samples with defined MERS-CoV RNA concentrations (10 Results: MERS-CoV strain-specific testing showed consistent virus antigen detection for both applied MERS-CoV isolates, with no statistically significant differences in positivity thresholds. A receiver operating characteristic (ROC) curve analysis based on the 2,736 archived MERS-CoV clade C RNA-pretested camel samples identified a limit of detection (LOD) of 1.53 × 10 Conclusion: The commercial Bionote MERS-CoV antigen test kit demonstrates reliable, clade-independent detection, enabling rapid MERS-CoV surveillance in camels in high-risk settings. The majority of antigen-positive samples contained infectious virus suggesting its applicability for assessing infection risks at slaughterhouses by the rapid test. The successful identification of MERS-CoV-infected camels at the point of slaughter underscores the critical importance of rapid diagnostics in high-exposure environments to mitigate zoonotic transmission and protect the health of slaughterhouse workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.